Just a Minute: The Final Step in Advisory Committee Process
This article was originally published in RPM Report
Executive Summary
FDA’s advisory committee process is a critical part of the new drug approval process. But the official record keeping of the committees is not: there is no real role for the “minutes” FDA publishes summarizing the panel deliberations.
You may also be interested in...
Mis-Reading the Minutes: Arena Approval Follows Sell-Off Based on Advisory Committee Summary
Arena received great news June 27: approval of the weight loss therapy Belviq with a very clean label and no special marketing restrictions. That was what Wall Street expected—except when investors read the summary of the advisory committee review of the drug published by FDA on June 22.
The Inevitable Outcome: Diabetes Safety Model Expands To Weight Loss…And Beyond?
The cardiovascular outcomes standard used for diabetes drugs since 2008 is moving to weight loss. That is important in itself, but also for what it says about the lessons FDA has taken from the diabetes experience – and what it might mean about regulatory expectations for other chronic drug classes in the future.
The Inevitable Outcome: Diabetes Safety Model Expands to Weight Loss…and Beyond?
The cardiovascular outcomes standard used for diabetes drugs since 2008 is moving to weight loss. That is important in itself, but also for what it says about the lessons FDA has taken from the diabetes experience—and what it might mean about regulatory expectations for other chronic drug classes in the future.